Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Overview
Date Founded

2011

Headquarters

181 Oyster Point Boulevard,South San Francisco, CA 94080

Type of Company

Public

Employees (Worldwide)

389

Industries

Pharmaceuticals
Medical Support Services
Holding Companies
Biotechnology

Company Description

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Global Blood Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer & Chief Accounting Officer

Chief Commercial Officer

Chief Legal Officer

Chief Business & Strategy Officer

Chief Human Resources Officer

Executive Vice President, Head-Research & Development

Senior Vice President, Head of Medical Affairs & Program Team Leader, Voxelotor

Chief Business Officer

Head of Intellectual Property

Board of Directors

ARCA biopharma, Inc.

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Chairman & Chief Executive Officer at San Francisco State University - The Willie L. Brown, Jr. Institute of Politics & Public Service

Founding Director at Stanford Distinguished Careers Institute

Former Governor of Massachusetts

Former Chief Marketing Officer & Executive Vice President at Merck & Co., Inc.

Chief Medical Officer & Senior Vice President at Bioverativ Therapeutics, Inc.

Former President-Europe & Canada Region at Merck & Co., Inc.

Partner at Corvus Pharmaceuticals, Inc.

Associate Director-Equity & Minority Health at Northwestern University - Feinberg School of Medicine

Paths to Global Blood Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Global Blood Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

Casdin Capital seeks to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Their portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, the firm also has discretion to invest in certain foreign equity securities if they determine that investments in such securities could generate risk-adjusted returns for their clients. Casdin Capital employs a primary research-intensive approach to investing that is thematically driven and fundamentally based and uses a range of investment strategies, primarily investing in publicly-traded equity or equivalent securities, both long and short, as well as a broad array of other securities.

Details Hidden

Great Point Partners seeks to achieve positive excess returns by investing in publicly traded biotechnology, pharmaceutical and life science companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Their hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. Great Point Partners targets fast-growing, technology- driven small-cap companies. In addition, the firm manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies.

Recent Transactions
Details Hidden

Global Blood Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Global Blood Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Global Blood Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onGlobal Blood Therapeutics, Inc. issued . USD Common Stock

Escrow Agent

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Head of Investment Banking

Advised onGlobal Blood Therapeutics, Inc. issued . USD Common Stock

Director

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Senior Counsel at Davis Polk & Wardwell LLP

Advisor

Executive Vice President, Head-Research & Development at Global Blood Therapeutics, Inc.

Senior Advisor

Former Inventor of the Anti-Epileptic Drug Vigabatrin at Merrell Dow Pharmaceuticals, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$2.4B
Total Enterprise Value
$2.33B
Earnings Per Share
$-4.04
Revenue
$124M
Net Profit
$-248M
TEVNet Income
-9.41x
Debt TEV
0.1x
Total Equity
$416M
EBITDA
$-233M
Total Debt
$233M
Enterprise Value / Sales
18.81x
EBITDAMargin
-188.47%
Non-Profit Donations & Grants
Investors
Details Hidden

The Vanguard Group is an American investment management company based in Malvern, Pennsylvania, that manages approximately $3.4 trillion[1] in assets. It is the largest provider of mutual funds and now the second-largest provider of exchange-traded funds (ETFs) in the world after BlackRock, with about $451 billion in ETF assets under management, as of March 2015.[3] It offers mutual funds and other financial products and services to retail and institutional investors in the United States and abroad. Founder and former chairman John C. Bogle is credited with the creation of the first index fund available to individual investors,[4] the popularization of index funds generally,[5] and driving costs down across the mutual fund industry.

Details Hidden

Third Rock Ventures invests in companies located in the US. The firm targets operating in the fields of healthcare sector. It provides financing for early-stage capital requirements. It also acts as a lead investor.

Details Hidden

Deerfield Management Co. LP invests in companies located in the US. The firm target companies operating in broad range of industries. They provides financing for buyout transactions to private and public.

Suppliers
University of California Holding Companies | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Roche Holding AG Hospitals & Patient Services | Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Syros Pharmaceuticals, Inc. Biotechnology | Cambridge, MA

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Competitors
Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Emmaus Life Sciences, Inc. Pharmaceuticals - Torrance, CA

Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company was founded on March 20, 1987 and is headquartered in Torrance, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Global Blood Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Global Blood Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Global Blood Therapeutics, Inc..